STK11 inhibits the mammalian target of rapamycin (mTOR) pathway (Martin and St Johnston, 2003; Baas et al., 2004; Zhang et al., 2021), and its mutations are linked to various tumor types in both syndromic and sporadic contexts (Carretero et al., 2010). This evidence concerns the gene MTOR and neoplasm.